Anaplastic Large Cell Lymphoma, ALK-Positive

Anaplastic Large Cell Lymphoma, ALK-Positive — Trials · CancerIndex

Clinical trials

Registered studies

20 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 6
Recruiting: 3
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: Baylor College of Medicine
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03719898	Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma	withdrawn	Phase 2	0	Fox Chase Cancer CenterOTHER	1	Jan 5, 2021	clinicaltrials
NCT02729961	Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma	withdrawn	Phase 1 / Phase 2	0	University of WashingtonOTHER	1	Oct 10, 2019	clinicaltrials